WIXOM, Mich., Oct. 5, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, reported today that it has appointed Carl Belczynski, PhD as Vice President of Investor Relations. He will report to Chairman and CEO Rob Chioini.
Mr. Belczynski brings more than 15 years of experience from the capital markets, where he worked as a sell-side analyst, portfolio manager and investment banker. Since 2008 he has served as Vice President, Healthcare Equity Capital Markets at JMP Securities. Prior to that, he was a portfolio manager for medical technology and biotechnology at Millennium Partners and Panacea Asset Management. Previous to that, he worked as a sell-side research analyst in medical technology at Vector Securities International.
"We are excited to have Carl join Rockwell," stated Robert L. Chioini, Chairman, CEO and President of Rockwell Medical. "Carl has extensive experience as a sell-side analyst, portfolio manager and investment banker and will focus on investor relations activities for the Company, as well as assist in business development initiatives relating to our clinical development business."About Rockwell Medical: Rockwell Medical is a fully-integrated biopharmaceutical company offering innovative products and services initially targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia. An established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad, Rockwell provides products that are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Dialysis is a process that duplicates kidney function for patients who suffer from ESRD. There are approximately 400,000 ESRD patients in the United States, a prevalence growing at an annual rate of 4 percent, and approximately 2 million ESRD patients world-wide.